These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Autism and associated disorders: cannabis as a potential therapy. Babayeva M; Assefa H; Basu P; Loewy Z Front Biosci (Elite Ed); 2022 Jan; 14(1):1. PubMed ID: 35320905 [TBL] [Abstract][Full Text] [Related]
28. Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents. Lamy M; Pedapati EV; Dominick KL; Wink LK; Erickson CA Paediatr Drugs; 2020 Oct; 22(5):473-483. PubMed ID: 32686015 [TBL] [Abstract][Full Text] [Related]
29. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034 [TBL] [Abstract][Full Text] [Related]
30. Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder. Román V; Adham N; Foley AG; Hanratty L; Farkas B; Lendvai B; Kiss B Psychopharmacology (Berl); 2021 Sep; 238(9):2381-2392. PubMed ID: 34264367 [TBL] [Abstract][Full Text] [Related]
31. Cannabidiol as a Potential Treatment for Anxiety Disorders. Blessing EM; Steenkamp MM; Manzanares J; Marmar CR Neurotherapeutics; 2015 Oct; 12(4):825-36. PubMed ID: 26341731 [TBL] [Abstract][Full Text] [Related]
32. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder. Poleg S; Kourieh E; Ruban A; Shapira G; Shomron N; Barak B; Offen D Transl Psychiatry; 2021 Oct; 11(1):524. PubMed ID: 34645786 [TBL] [Abstract][Full Text] [Related]
33. Inattention and hyperactivity/impulsivity among children with attention-deficit/hyperactivity-disorder, autism spectrum disorder, and intellectual disability. McClain MB; Hasty Mills AM; Murphy LE Res Dev Disabil; 2017 Nov; 70():175-184. PubMed ID: 28957735 [TBL] [Abstract][Full Text] [Related]
34. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Silva EAD; Medeiros WMB; Torro N; Sousa JMM; Almeida IBCM; Costa FBD; Pontes KM; Nunes ELG; Rosa MDD; Albuquerque KLGD Trends Psychiatry Psychother; 2022 Jun; 44():e20200149. PubMed ID: 34043900 [TBL] [Abstract][Full Text] [Related]
35. Treatment of Autism Spectrum Disorder in Children and Adolescents. DeFilippis M; Wagner KD Psychopharmacol Bull; 2016 Aug; 46(2):18-41. PubMed ID: 27738378 [TBL] [Abstract][Full Text] [Related]
36. Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders. Canitano R Clin Neuropharmacol; 2015; 38(5):177-82. PubMed ID: 26366961 [TBL] [Abstract][Full Text] [Related]
37. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Politte LC; Scahill L; Figueroa J; McCracken JT; King B; McDougle CJ Neuropsychopharmacology; 2018 Jul; 43(8):1772-1778. PubMed ID: 29540864 [TBL] [Abstract][Full Text] [Related]
38. Effects of CBD-Enriched Fleury-Teixeira P; Caixeta FV; Ramires da Silva LC; Brasil-Neto JP; Malcher-Lopes R Front Neurol; 2019; 10():1145. PubMed ID: 31736860 [TBL] [Abstract][Full Text] [Related]
39. Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD. Naguy A J Nerv Ment Dis; 2017 Sep; 205(9):738. PubMed ID: 28846573 [No Abstract] [Full Text] [Related]
40. Inattention and hyperactive/impulsive component scores do not differentiate between autism spectrum disorder and attention-deficit/hyperactivity disorder in a clinical sample. Krakowski AD; Cost KT; Anagnostou E; Lai MC; Crosbie J; Schachar R; Georgiades S; Duku E; Szatmari P Mol Autism; 2020 Apr; 11(1):28. PubMed ID: 32334619 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]